
Hansa Biopharma to present positive 12-month Phase 3 kidney transplant trial results at American Transplant Congress.
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...


